Brief: Immunovia Q3 Net Loss Widens To SEK 25.6 Mln

Immunovia AB (publ)

08/11/2019 13:04

Nov 8 (Reuters) - Immunovia AB (publ)  IMMNOV.ST :
    * IMMUNOVIA INTERIM REPORT, JANUARY-SEPTEMBER 2019
    * Q3 NET SALES SEK 92,000 VERSUS SEK 85,000 YEAR AGO
    * Q3 NET LOSS SEK 25.6 MILLION VERSUS LOSS SEK 17.4 MILLION
YEAR
AGO
    * WE REMAIN FULLY COMMITTED AND FOCUSED ON IMMRAY PANCAN-D
    * WE CONTINUE TO BE ON-SCHEDULE AND WORK INTENSELY FOR ALL
PREPARATIONS FOR OUR PLANNED LAUNCH OF IMMRAY PANCAN-D IN Q3
2020
    * BRINGING IMMRAY PANCAN-D TO MARKET AND DOMINATING MARKET
FOR
EARLY DETECTION OF PANCREATIC CANCER IN FORESEEABLE FUTURE IS AN
OPPORTUNITY WITH TOTAL ESTIMATED MARKET POTENTIAL OF USD 4.4
BILLION IN US AND EUROPE ALONE, AND IS NOW WITHIN OUR REACH

Source text for Eikon:  ID:nWkr2FBfFZ 
Further company coverage:  IMMNOV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))